Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 851-856

  Margolin, K ^a   Gordon, M S ^a   Holmgren, E ^a   Gaudreault, J ^a   Novotny, W ^a   Fyfe, G ^a   Adelman, D ^a   Stalter, S ^a   Breed, J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY VEGF; PACLITAXEL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0035253586     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.851     Document Type: Article

References (25)

1. What is the evidence that tumors are angiogenesis dependent?
2. Clinical applications of research on angiogenesis
3. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
4. Current controversies in cancer: Is determination of angiogenic activity in human tumours clinically useful?
5. Tumor vascularity as a prognostic factor in cancer
6. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy
7. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo
8. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
9. Molecular and biological properties of the vascular endothelial cell growth factor family of proteins
10. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
11. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
12. Oncogenes, p53, and tumor angiogenesis
13. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
14. The biology of vascular endothelial growth factor
15. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
16. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies
17. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice
18. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
19. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
20. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
21. A cancer therapy resistant to resistance
22. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
23. Actions of heparin that may affect the malignant process
24. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells